
Tesamorelin
U.S. FDA — approuvé pour Reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy (United States (FDA), sous le nom Egrifta / Egrifta SV / Egrifta WR).
The approval is specific to this one indication and population — it does not cover general body-composition, anti-aging or performance use, which is off-label, and is not a statement that Regenexa's research-use tesamorelin product is itself an approved medicine.
Source : FDA drug label — EGRIFTA (tesamorelin for injection) · vérifié le 2026-07-26








































